Related Experiment Video
Updated: May 28, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
[Advances in molecular genetics and treatment of gliomas]
1Neurologie Mazarin et CRICM-INSERM U975, Hôpital de la Salpêtrière--Paris. khe.hoang-xuan@psl.aphp.fr
Abstract:
Malignant gliomas are histologically and clinically heterogeneous tumors carrying a poor prognosis despite surgery, radiotherapy and chemotherapy. Recent molecular genetic studies have led to the classification of gliomas into distinct biological entities with prognostic significance, and to the identification of new therapeutic targets. Advances in our knowledge of gliomagenesis and the biological bases of chemoresistance hold promise for improved patient management. We are entering a new era in which individualized and targeted treatment (antiangiogenic therapy, signaling pathway inhibitors) will become increasingly important, in conculsion with conventional treatments and guided by plasma and tumor biomarkers.
Insights
Malignant gliomas are heterogeneous tumors with poor prognosis. New molecular insights are enabling targeted therapies and personalized treatment strategies for improved patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer Genetics
- Translational Medicine
Background:
- Malignant gliomas are aggressive brain tumors with limited treatment efficacy.
- Tumor heterogeneity and chemoresistance contribute to poor patient prognosis.
- Advances in molecular genetics are redefining glioma classification and therapeutic targets.
Purpose of the Study:
- To review the impact of molecular genetic studies on understanding glioma biology.
- To highlight the potential of novel targeted therapies and personalized treatment approaches.
- To discuss the integration of biomarkers in guiding future glioma management.
Main Methods:
- Review of recent molecular genetic studies in glioma research.
- Analysis of findings related to gliomagenesis and chemoresistance.
- Synthesis of information on emerging targeted treatments and biomarkers.
Main Results:
- Molecular classification has identified distinct glioma subtypes with prognostic value.
- New therapeutic targets, including antiangiogenic agents and pathway inhibitors, have been identified.
- Understanding gliomagenesis and chemoresistance mechanisms is crucial for treatment optimization.
Conclusions:
- Individualized and targeted treatments, combined with conventional therapies, represent the future of malignant glioma management.
- Plasma and tumor biomarkers will play a key role in guiding personalized treatment decisions.
- Continued research into glioma biology promises improved patient outcomes.
More Related Videos
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
10:58Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
